ReviewTherapeutic advances in infectious disease2017
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.
Review in Therapeutic advances in infectious disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.The Journal of antimicrobial chemotherapy · 2026Article
- Article
- Global burden of antimicrobial-resistant Staphylococcus aureus lower respiratory tract infections in older adults: a secondary analysis of the MICROBE database (1990-2021).BMC infectious diseases · 2026Article
- Targeting biofilm-driven antibiotic resistance: emerging mechanisms and next-generation therapeutic interventions.Frontiers in microbiology · 2026Review
- Antimicrobial Resistance - The 'Real' Pandemic We Are Unaware Of, Yet Nearby.Journal of Korean medical science · 2025Review
- Antimicrobial peptides: a promising frontier to combat antibiotic resistant pathogens.Annals of medicine and surgery (2012) · 2025Review
- Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia.Cureus · 2025Article
- Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.Infection and drug resistance · 2025Review
- RapidAntimicrobial agents and chemotherapy · 2024Article
- New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection.Pharmaceutics · 2023Article
- Review
- Synthetic and Semisynthetic Compounds as Antibacterials Targeting Virulence Traits in Resistant Strains: A Narrative Updated Review.Antibiotics (Basel, Switzerland) · 2023Review
- Extensive spinal epidural abscess caused by Staphylococcus epidermidis: A case report and literature review.Frontiers in surgery · 2023Article
- Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.ACS infectious diseases · 2022Review
- Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria.The Korean journal of internal medicine · 2022Review
- WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections.World journal of emergency surgery : WJES · 2022Review
- A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides.International journal of molecular sciences · 2020Review
- Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.Frontiers in pharmacology · 2019Review
Corrections and comments
- Erratum issuedCorrigendum.2017
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telavancin (TD-6424), a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.